Schollhammer, R., De Clermont Gallerande, H., Yacoub, M., Quintyn Ranty, M., Barthe, N., Vimont, D., . . . Morgat, C. (2019). Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples. EJNMMI research, 9(1), 1-7. https://doi.org/10.1186/s13550-019-0517-6
Citace podle Chicago (17th ed.)Schollhammer, Romain, Henri De Clermont Gallerande, Mokrane Yacoub, Marie-Laure Quintyn Ranty, Nicole Barthe, Delphine Vimont, Elif Hindié, Philippe Fernandez, a Clément Morgat. "Comparison of the Radiolabeled PSMA-inhibitor 111In-PSMA-617 and the Radiolabeled GRP-R Antagonist 111In-RM2 in Primary Prostate Cancer Samples." EJNMMI Research 9, no. 1 (2019): 1-7. https://doi.org/10.1186/s13550-019-0517-6.
Citace podle MLA (9th ed.)Schollhammer, Romain, et al. "Comparison of the Radiolabeled PSMA-inhibitor 111In-PSMA-617 and the Radiolabeled GRP-R Antagonist 111In-RM2 in Primary Prostate Cancer Samples." EJNMMI Research, vol. 9, no. 1, 2019, pp. 1-7, https://doi.org/10.1186/s13550-019-0517-6.